| Literature DB >> 26508303 |
Atsebaha Gebrekidan1, Tsehaye Asmelash Dejene2, Getahun Kahsay3, Araya Gebreysus Wasihun4.
Abstract
BACKGROUND: Emergence of increased antimicrobial resistance of Shigella species is a global challenge, particularly in developing countries where increased misuse of antimicrobial agents occurs. There is no published data in the study area on the prevalence and antimicrobial susceptibility patterns of Shigella among acute diarrheal patients. This study was therefore, under taken to fill this gap.Entities:
Mesh:
Year: 2015 PMID: 26508303 PMCID: PMC4624588 DOI: 10.1186/s13104-015-1606-x
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Prevalence of Shigella by age and gender among outpatients with acute diarrhea at Mekelle hospital, (August–November, 2014)
| Characteristics | Total patients, N (%) | Positive isolates (%) | X2 |
|
|---|---|---|---|---|
| Gender | ||||
| Male | 109 (50.9) | 7 (6.4) | 0.093 | 0.76 |
| Female | 107 (49.5) | 8 (7.5) | ||
| Age of patients (in years) | ||||
| ≤15 | 80 (37) | 10 (12.5) | 11.52 | 0.005 |
| 16-30 | 82 (38) | 2 (2.4) | ||
| 31–45 | 29 (13.4) | 0 (0.0) | ||
| ≥46 | 25 (11.6) | 3 (12) | ||
Prevalence of Shigella by clinical symptoms and risk factors among acute diarrhea patients at Mekelle hospital (August to November, 2014)
| Characteristics | Patients, N (%) | Positive isolates (%) | X2 | P value |
|---|---|---|---|---|
| Fever | ||||
| Yes | 87 (40.3) | 7 (8) | NA | NA |
| No | 129 (59.7) | 8 (6.2) | ||
| Vomiting | ||||
| Yes | 88 (40.7) | 4 (4.5) | NA | NA |
| No | 128 (59.3) | 11 (8.6) | ||
| Abdominal cramp | ||||
| Yes | 136 (63) | 11 (8.1) | NA | NA |
| No | 80 (37) | 4 (5) | ||
| Duration of diarrhea | ||||
| 1–5 days | 150 (69.4) | 6 (4) | NA | NA |
| 6–10 days | 34 (15.7) | 4 (11.8) | ||
| 11–14 days | 32 (14.8) | 5 (15.6) | ||
| Consistency of diarrhea | ||||
| Watery | 78 (36.1) | 5 (6.4) | NA | NA |
| Mucus | 93 (43.1) | 2 (2.2) | ||
| Bloody | 19 (8.8) | 4 (21.1) | ||
| Mucus + blood | 26 (12) | 4 (15.4) | ||
| Presence of latrine at home | ||||
| Yes | 169 (78.2) | 7 (4.1) | ||
| No | 47 (21.8) | 8 (17) | 7.5 | 0.002 |
| Source of drinking water | ||||
| Private pipe water | 154 (71.3) | 6 (3.9) | ||
| Public pipe water | 37 (17.1) | 6 (16.2) | ||
| Well | 25 (11.6) | 3 (12) | 9.19 | 0.027 |
| Hand washing habit before meal | ||||
| Yes | 154 (71.3) | 7 (4.5) | ||
| No | 62 (28.7) | 8 (12.9) | 4.78 | 0.029 |
| Hand washing habit | ||||
| With soap | 36 (23.4) | 1 (2.8) | ||
| Without soap | 118 (76.6) | 6 (5.1) | 0.338 | 0.561 |
NA not applicable as they are not predisposing factors
Fig. 1Antimicrobial resistance patterns of Shigella isolates from diarrheic outpatients at Mekelle hospital (August to November, 2014)
Multidrug resistance pattern of Shigella isolates from outpatients with acute diarrhea at Mekelle hospital (September to November, 2014)
| Number of antimicrobial resistance |
| |
|---|---|---|
| Resistance antibiograma | Number of isolates (%) | |
| Ro | None | None |
| R1 | AMP | 1 (6.7) |
| R2 | AMP, AML | 1 (6.7) |
| AMP, AMC | 1 (6.7) | |
| R3 | AMP, C, AML | 1 (6.7) |
| AMP, AML, SXT | 1 (6.7) | |
| R4 | AMP, C, AML, SXT | 4 (26.7) |
| AMP, AML, AMC, SXT | 3 (20) | |
| AMP, C, AML, AMC | 1 (6.7) | |
| R5 | AMP, AML, SXT, CIP, CN | 1 (6.7) |
| R6 | AMP, C, AML, SXT, NOR, CN | 1 (6.7) |
AMP amoxicillin, C chloramphenicol, AML amoxicillin, AMC amoxicillin clavulanic acid, SXT sulphamethoxazole trimethoprim, NOR norfloxacin, CIP ciprofloxacin, CN gentamicin
aRo, R1,R2,R3,R4,R5,R6 = Sensitive to all, resistant to one, two, three, four, five and six antibiotics respectively
Pattern of prevalence and antimicrobial resistance patterns of Shigella reported from 2001 to 2014 in Ethiopia
| Study area | Authors | Prevalence | Amp | Cot | C | NOR | CIP | CN | AMC | AMX |
|---|---|---|---|---|---|---|---|---|---|---|
| Gondar | Yismaw et al. [ | 7.4 | 79.9 | 73.4 | 52.2 | – | 8.9 | 7.9 | – | – |
| Huruy et al. [ | 16.8 | 81.5 | 75.4 | 50.8 | – | 9.2 | 10.7 | – | – | |
| Tiruneh [ | 7.5 | 78.9 | 84.6 | 67.8 | 1.1 | 2.2 | 12.2 | – | – | |
| Demissie et al. [ | 4.57 | 94.1 | 58.8 | 17.6 | – | 0.0 | 41.7 | – | – | |
| Harar | Reda et al. [ | 6.7 | 100 | 5.9 | 29.4 | – | – | 0.0 | – | 100 |
| Bahir Dar | Debas et al. [ | 14.5 | – | – | – | 9.4 | 0.0 | 25 | – | 88.2 |
| Hawassa | Mulatu et al. [ | 7 | 63 | 0.0 | 9.1 | – | 0.0 | 27.3 | – | 100 |
| Butajira | Mengstu et al. [ | 4.5 | 47.1 | 76.5 | 29.4 | – | 5.9 | 17.6 | – | – |
| Jimma | Mache [ | 20.1 | 70.1 | 32.5 | 40.3 | 1.3 | – | – | ||
| Beyene and Tasew [ | 2.3 | 100 | 100 | 16.7 | – | – | 0.0 | – | 100 | |
| Mekelle | This study | 6.9 | 100 | 66.7 | 46.7 | 6.7 | 6.7 | 13.3 | 33.3 | 86.7 |
AMP amoxicillin, C chloramphenicol, AML amoxycillin, AMC amoxycillin Clavulanic acid, SXT sulphamethoxazole trimethoprim, NOR norfloxacin, CIP ciprofloxacin, CN gentamicin